newsfilter
← Latest News
GlobeNewswire·

Principia Announces Expanded Development Program to Broaden BTK Footprint in Immune-Mediated Diseases

Company’s lead candidate PRN1008 receives generic name -- rilzabrutinib Rilzabrutinib to enter clinical trial in IgG4-Related Disease SOUTH SAN FRANCISCO, Calif., Jan. 07, 2020 (GLOBE...